We are pleased to announce the upcoming conference hosted by the Eira Initiative in association with the Berkeley Policy Institute: Competing for the Cure: Intellectual Property, Innovation Policy, and Biopharmaceutical Ecosystems (October 29–30, 2026).
Read MoreEira Initiative
Evergreening's Empirical Chasm: A Working Paper from the Eira Initiative
A working paper from the Eira Initiative examines data on pharmaceutical innovation. The author, Professor Erika Lietzan, finds that the evergreening narrative (which alleges companies patent revisions to drugs to prolong intellectual property protection) is conceptually flawed, misrepresents how patents and exclusivity intersect with drug approval frameworks, and risks misleading policymakers into enacting measures that would punish innovation to the detriment of patients.
Read MoreOp-Ed on Regulatory Exclusivity for Pharmaceutical Innovation
Many political leaders increasingly view regulatory exclusivity as a lucrative handout to pharmaceutical companies. In a new DC Journal op-ed, Professor Kristina M. L. Acri née Lybecker explains why that narrative is mistaken -- and cautions against policies that would weaken exclusivity and discourage the investments that lead to new medicines.
Read MoreNew Policy Brief: The Economics of Skinny Labels
With the Supreme Court set to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., key questions are coming into focus. How might the Court's decision reshape strategies for brand-name and generic manufacturers? And what risks will companies face when marketing “skinny label” products?
Read More